Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Kidney

Kidney

20

Pipeline Programs↗

37

Active Trials↗

22

Companies Involved↗

Kidney is an emerging landscape with 20 programs across 22 companies. The most active players are Hansa Biopharma AB. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

52/100

Mech. Concentration

9/100

Completion Rate

82/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Hansa Biopharma AB

1 program

Pipeline

Programs by Phase

Preclinical7

Tocilizumab

Celltrion

CD38

wujianyong

Azathioprine

Legacy Health System

Terlipressin

Mallinckrodt

Sevoflurane

AbbVie

Phase 14

Peptide Vaccine

University Hospital Tuebingen

QS21

Memorial Sloan Kettering Cancer Center

Blinatumomab Treatment

The Children's Hospital of Zhejiang University School of Medicine

Teclistamab Treat

West China Hospital

Phase 27

Cemiplimab

Regeneron

Prednisone

Roxane Laboratories

Sirolimus

Prism Pharmaceuticals

Cetuximab

Imclone

Imlifidase

Hansa Biopharma AB

Phase 32

Trimethoprim-Sulfamethoxazole

Astellas

Eplerenone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

No programs

Analysis

Modality Breakdown

69%

Small molecule

11 of 16 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 85% of 20 pipeline programs.

Analysis

Trial Status

73

clinical trials

Completed27 · 37%

Not yet recruiting20 · 27%

Recruiting13 · 18%

Terminated5 · 7%

Active, not recruiting4 · 5%

Unknown status3 · 4%

Other1 · 1%

Clinical Trials

Trial Activity

73 trials

Kidney Sodium Content in Cardiorenal Patients

Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT04170855·50 enrolled

Mechanism of SGLT2 Inhibition in the Kidney

Recruiting·UUniversity of Michigan·Phase 4·NCT06291155·20 enrolled

Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys

Recruiting·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 3·NCT05430620·60 enrolled

Advancing Transplantation Outcomes in Children (CTOT-41)

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06055608·200 enrolled

Multicenter, Prospective and Open-label Clinical Trial to Evaluate the Viability, Performance and Safety of ex Vivo Normothermic Perfusion in Kidney Transplantation From DCD and DBD Donors.

Recruiting·EEbers Medical Technology, S.L.·Preclinical·NCT05175885·100 enrolled

A Single-center, Non-randomized, Uncontrolled Pilot Study on Hypothermic Machine Perfusion With Omnisol Preservation Solution of Deceased Donor Kidneys Prior to Transplantation

Recruiting·VVivalyx GmbH·Preclinical·NCT07792317·15 enrolled

Multiparametric MRI in a Prospective Cohort of Living Kidney Donors, Recipients, and Healthy Controls: Correlations With Markers of Renal Function, Fibrosis and Ageing

Recruiting·—·N/A·NCT06210555·96 enrolled

A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment

Recruiting·HHansa Biopharma AB·Phase 2·NCT05753930·10 enrolled

The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation (Biome-KT)

Recruiting·UUniversity of Illinois at Chicago·N/A·NCT06206486·133 enrolled

Comparative Effects of Propofol and Sevoflurane Anesthesia in Living Kidney Donors on Perioperative Plasma miR-146a, miR-155, and miR-21 Levels: A Randomized Prospective Comparative Trial

Recruiting·UUniversity of Gaziantep·Preclinical·NCT07760402·34 enrolled

Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection

Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT06351488·319 enrolled

A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT06741072·55 enrolled

Prevention of Weight Gain and Impaired Glucose Metabolism Post Kidney Transplantation: A Pilot and Feasibility Study

Recruiting·UUniversity of Kansas Medical Center·Preclinical·NCT06640179·60 enrolled

A Multicenter, Randomized, Double-blind, Positive-control, Non-inferiority Clinical Trial on the Effectiveness and Safety of HCA-N Solution for the Preservation of Kidney Grafts During Kidney Transplantation

Active, not recruiting·ZZhongnan Hospital·Preclinical·NCT07825025·250 enrolled

A Prospective Controlled Trial to Evaluate Safety and Efficacy of in Vitro Expanded Recipient Regulatory T Cell Therapy and Tocilizumab Together With Donor Bone Marrow Infusion in HLA-mismatched Living Donor Kidney Transplant Recipients

Active, not recruiting·—·Preclinical·NCT03867617·12 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)